Boule Diagnostics AB - Asset Resilience Ratio
Boule Diagnostics AB (BOUL) has an Asset Resilience Ratio of 4.94% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Boule Diagnostics AB (BOUL) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2024)
This chart shows how Boule Diagnostics AB's Asset Resilience Ratio has changed over time. See BOUL total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Boule Diagnostics AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Boule Diagnostics AB (BOUL) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr23.00 Million | 4.94% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr23.00 Million | 4.94% |
Asset Resilience Insights
- Limited Liquidity: Boule Diagnostics AB maintains only 4.94% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Boule Diagnostics AB Industry Peers by Asset Resilience Ratio
Compare Boule Diagnostics AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 7.79% |
|
Beijing Wandong Medical Technology Co Ltd
SHG:600055 |
Medical Devices | 4.92% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
MODULIGHT OY EO 1
F:78W |
Medical Devices | 22.31% |
|
Diagnostic Medical Systems SA
PA:ALDMS |
Medical Devices | 1.39% |
|
Theradiag SA
PA:ALTHE |
Medical Devices | 15.59% |
|
Nova EYE Medical Ltd
AU:EYE |
Medical Devices | 11.08% |
Annual Asset Resilience Ratio for Boule Diagnostics AB (2010–2024)
The table below shows the annual Asset Resilience Ratio data for Boule Diagnostics AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.48% | Skr26.43 Million ≈ $2.84 Million |
Skr590.20 Million ≈ $63.51 Million |
-0.45pp |
| 2023-12-31 | 4.93% | Skr37.23 Million ≈ $4.01 Million |
Skr755.11 Million ≈ $81.26 Million |
-1.80pp |
| 2022-12-31 | 6.73% | Skr51.11 Million ≈ $5.50 Million |
Skr759.96 Million ≈ $81.78 Million |
+6.49pp |
| 2021-12-31 | 0.24% | Skr1.36 Million ≈ $146.36K |
Skr572.03 Million ≈ $61.56 Million |
+1.04pp |
| 2020-12-31 | -0.80% | Skr-3.83 Million ≈ $-411.85K |
Skr479.71 Million ≈ $51.62 Million |
+3.58pp |
| 2019-12-31 | -4.38% | Skr-25.70 Million ≈ $-2.77 Million |
Skr586.87 Million ≈ $63.16 Million |
-2.21pp |
| 2018-12-31 | -2.17% | Skr-10.86 Million ≈ $-1.17 Million |
Skr500.85 Million ≈ $53.90 Million |
-25.98pp |
| 2017-12-31 | 23.81% | Skr99.16 Million ≈ $10.67 Million |
Skr416.49 Million ≈ $44.82 Million |
+11.57pp |
| 2016-12-31 | 12.24% | Skr44.59 Million ≈ $4.80 Million |
Skr364.33 Million ≈ $39.21 Million |
-30.74pp |
| 2010-12-31 | 42.98% | Skr88.58 Million ≈ $9.53 Million |
Skr206.11 Million ≈ $22.18 Million |
-- |
About Boule Diagnostics AB
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clini… Read more